Xenex LightStrike Disinfection Robots Now Available in UK Via ESPO Framework
LightStrike robots emit high intensity bursts of broad spectrum ultraviolet (UV) light proven to deactivate severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19, in 2 minutes at 1 meter, according to a peer-reviewed study published in Infection Control and Hospital Epidemiology. LightStrike robots are also proven to quickly destroy pathogens including Clostridioides difficile (C. diff), methicillin-resistant Staphylococcus aureus (MRSA or staph), vancomycin-resistant enterococcus (VRE), influenza, and other multi-drug resistant organisms. Different pathogens are susceptible to UV light at different wavelengths. With bursts of broad spectrum UV light (200-315nm) generated by a pulsed xenon lamp, LightStrike robots quickly deactivate viruses and bacteria where they are most vulnerable without damaging surfaces or materials.
Xenex recently expanded its global presence to include a UK-based direct sales team. Organizations interested in purchasing LightStrike robots via the ESPO Framework should visit https://www.espo.org/frameworks.html or contact firstname.lastname@example.org.
Xenex is a world leader in UV technology-based disinfection strategies and solutions. Frost & Sullivan named Xenex the 2020 Global Company of the Year for its patented technology and being at the vanguard of the fight against SARS-CoV-2. Xenex is focused on developing, manufacturing and commercializing products and services that utilize its innovative, proprietary disinfection technologies to eliminate the spread of deadly pathogens that cause infectious diseases. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures. For more information, visit xenex.com.